Associated Papers
Contrasting Effects of Cancer-Associated Mutations in EphA3 and EphB2 Kinases.
Kim Y et al.
Biochemistry, 2024
Landscape of drug-resistance mutations in kinase regulatory hotspots.
Kim P et al.
Briefings in Bioinformatics, 2021
KinaseMD: kinase mutations and drug response database.
Hu R et al.
Nucleic Acids Research, 2021
33137204 (PubMed )
Supplement: gkaa945_supplemental_files.zip › Supplementary_Table_S3.xlsx › Sheet1
Somatically mutated ABL1 is an actionable and essential NSCLC survival gene.
Testoni E et al.
Embo Molecular Medicine, 2016
26758680 (PubMed )
Supplement: EMMM-8-105-s006.xlsx › H2126_mutations_cBio
Tongue carcinoma infrequently harbor common actionable genetic alterations.
Tan DS et al.
Bmc Cancer, 2014
Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study.
Okamoto I et al.
Oncotarget, 2014
24810493 (PubMed )
Supplement: oncotarget-05-2293-s001.pdf
Structure-functional prediction and analysis of cancer mutation effects in protein kinases.
Dixit A et al.
Computational and Mathematical Methods in Medicine, 2014
A high-content cellular senescence screen identifies candidate tumor suppressors, including EPHA3.
Lahtela J et al.
Cell Cycle (georgetown, Tex.), 2013
Effects of cancer-associated EPHA3 mutations on lung cancer.
Zhuang G et al.
Journal of the National Cancer Institute, 2012
Cancer somatic mutations disrupt functions of the EphA3 receptor tyrosine kinase through multiple mechanisms.
Lisabeth EM et al.
Biochemistry, 2012
Select a paper to view details